ClinPGx Blog

Sign in Subscribe

Latest — Nov 19, 2025

New PharmCAT release

Highlights of the latest releases (v3.1.0- v3.1.1) are: * CPIC function and phenotype assignments are used to provide genotype-level guidance from all sources including DPWG and FDA. For a detailed blog see, Genotype-Phenotype Mapping for Guideline and Drug Label Curation. * Allele definitions are up to date to

More issues

Genotype-Phenotype Mapping for Guideline and Drug Label Curation

ClinPGx now uses CPIC/ClinPGx allele function and phenotype mappings and terms for guideline and drug label curation, including the interactive genotype picker tools on DPWG guideline annotation pages. If a DPWG guideline gene is not a CPIC gene, then we will continue to use DPWG mappings based on documents

Updated FDA-approved label for Xeloda (capecitabine)

The FDA-approved label for Xeloda (capecitabine) was updated a week ago to include a boxed warning regarding adverse reactions in patients with complete DPD deficiency and to "Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary." This language is new. The

CPIC Guideline for NAT2 Genotype and Hydralazine Therapy

The CPIC Guideline for NAT2 Genotype and Hydralazine Therapy has been published in the journal Clinical Pharmacology and Therapeutics. This new guideline summarizes and evaluates literature evidence regarding the impact of genetic variants on NAT2's metabolism of hydralazine, a vasodilator typically used in the treatment of resistant hypertension

ClinGen Pharmacogenomics Interpretation Committee Publication on Survey Findings

We are excited to announce the publication of Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities (PMID: 40662343) by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC) in Genetics in Medicine. This publication covers the results of the PGxIC’s two needs assessment surveys targeting both

Announcing ClinPGx

We are excited to announce the official launch of the ClinPGx website! ClinPGx brings together trusted pharmacogenomics tools and resources, presented in an easy-to-navigate format. If you're familiar with PharmGKB, you'll find improved organization of the same reliable information, and some extra features. A short video

In Press: Survey Findings on Integrating Pharmacogenomics into Genomic Medicine

We’re excited to announce that our latest paper, titled “Towards an Integrated Resource for Pharmacogenomics (PGx): Survey Findings from the Genomic Medicine Communities,” is now in press in Genetics in Medicine! This work, conducted by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC, formerly the PGx Working Group), presents findings from

PharmGKB is moving to ClinPGx

Nearly two years ago, we introduced the vision for ClinPGx to integrate the PharmGKB, CPIC and PharmCAT projects into a unified resource. In June 2024, we launched the ClinPGx blog and held the first ClinPGx Meeting. We are excited to announce that over the coming weeks, PharmGKB will officially become

PharmGKB User Survey

PharmGKB is conducting a survey designed to gather user feedback to enhance our content, features and tools. Your insights are essential as PharmGKB transitions to ClinPGx this summer and we prepare our next grant application to support our ongoing project. We would be incredibly grateful for your thoughts on the

Recent Updates to PharmGKB’s Genotype Selection Interface (GSI) Tool

We are excited to announce that we have partnered with Dr. Emily Cicali on behalf of The University of Florida Health Precision Medicine Program to incorporate the information presented in the PROPTM pharmacogenetics calculator into the GSI. Users can select from a list of concomitant medications that are either strong